Literature DB >> 11122982

The neurobiology of social phobia: from pharmacotherapy to brain imaging.

M Van Ameringen1, C Mancini, P Farvolden, J Oakman.   

Abstract

Social phobia is a common psychiatric disorder that is often associated with significant psychiatric comorbidity and disability. There is currently considerable evidence for the efficacy of pharmacotherapy, especially the selective serotonin reuptake inhibitors, in the treatment of this disorder. In addition, researchers have recently begun to explore the underlying neurobiology of social phobia with results that will likely have important implications for future treatments. This article provides a review of the results to date of controlled medication trials. A review of chemical and neuroendocrine challenges, neurotransmitter functioning, and neuroimaging studies in social phobia is provided, followed by a discussion of the implications of these findings for future treatment and research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122982     DOI: 10.1007/s11920-000-0082-7

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  80 in total

1.  A predictive reinforcement model of dopamine neurons for learning approach behavior.

Authors:  J L Contreras-Vidal; W Schultz
Journal:  J Comput Neurosci       Date:  1999 May-Jun       Impact factor: 1.621

2.  Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects.

Authors:  M B Stein; M E Tancer; T W Uhde
Journal:  Arch Gen Psychiatry       Date:  1992-04

3.  Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.

Authors:  D Baldwin; J Bobes; D J Stein; I Scharwächter; M Faure
Journal:  Br J Psychiatry       Date:  1999-08       Impact factor: 9.319

4.  Placebo-controlled trial of moclobemide in social phobia.

Authors:  F R Schneier; D Goetz; R Campeas; B Fallon; R Marshall; M R Liebowitz
Journal:  Br J Psychiatry       Date:  1998-01       Impact factor: 9.319

Review 5.  Anxiety and Parkinson's disease.

Authors:  I H Richard; R B Schiffer; R Kurlan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1996       Impact factor: 2.198

6.  Magnetic resonance spectroscopy in social phobia: preliminary findings.

Authors:  J R Davidson; K R Krishnan; H C Charles; O Boyko; N L Potts; S M Ford; L Patterson
Journal:  J Clin Psychiatry       Date:  1993-12       Impact factor: 4.384

7.  Nefazodone for social phobia: a clinical case series.

Authors:  J J Worthington; B G Zucker; C S Fones; M W Otto; M H Pollack
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

8.  Pharmacotherapy for social phobia: what works, what might work, and what does not work at all.

Authors:  M Van Ameringen; C Mancini; P Farvolden; J Oakman
Journal:  CNS Spectr       Date:  1999-11       Impact factor: 3.790

9.  Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.

Authors:  I M van Vliet; J A den Boer; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.